Literature DB >> 2917275

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

B G Weinshenker1, B Bass, G P Rice, J Noseworthy, W Carriere, J Baskerville, G C Ebers.   

Abstract

The outcome of multiple sclerosis (MS), assessed according to the Kurtzke Disability Status Scale (DSS), was reviewed in 1,099 consecutive patients followed in London, Canada, between 1972 and 1984. A geographically based subgroup of 196 patients representing 90% of Middlesex County MS patients as well as a group of 197 patients seen from onset of disease were separately analysed. The clinical course was progressive from onset in 33% of the total population and in 28% of the Middlesex County subgroup. Of those with duration of 6-10 yrs, 30-40% with initially remitting disease developed progressive MS. The cross-sectional distribution of disability was bimodal with peaks at DSS 1 (no disability) and DSS 6 (assistance required for walking). Actuarial analysis showed that the median time to reach DSS 6 from onset of MS was 14.97 +/- 0.31 yrs in the total population and 9.42 +/- 0.44 yrs in the "seen from onset' subgroup. Survival was minimally altered; 87% of patients followed up to 40 yrs were still alive, although ascertainment of cases with this duration of MS was incomplete. Data describing the rate at which disability develops after the onset of a progressive phase of MS are also presented. The implications of these data in planning and interpretation of clinical therapeutic trials are discussed.

Entities:  

Mesh:

Year:  1989        PMID: 2917275     DOI: 10.1093/brain/112.1.133

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  273 in total

1.  Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.

Authors:  D Parkin; A Jacoby; P McNamee; P Miller; S Thomas; D Bates
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

2.  Reason for hope: the advent of disease-modifying therapies in multiple sclerosis.

Authors:  P W O'Connor
Journal:  CMAJ       Date:  2000-01-11       Impact factor: 8.262

3.  Natural history of multiple sclerosis.

Authors:  G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 4.  Immunologic therapy for relapsing-remitting multiple sclerosis.

Authors:  H J MacLean; M S Freedman
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

5.  Rehabilitation services remain important in multiple sclerosis.

Authors:  Richard Richards
Journal:  BMJ       Date:  2002-04-20

6.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

Review 7.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.

Authors:  D S Meier; H L Weiner; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2007 Nov-Dec       Impact factor: 3.825

9.  Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.

Authors:  Shien Guo; Duygu Bozkaya; Alexandra Ward; Judith A O'Brien; Khajak Ishak; Randy Bennett; Ahmad Al-Sabbagh; Dennis M Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 10.  Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Authors:  Regina Berkovich; Mark A Agius
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.